Kensey Nash Stock Price Up In January On St. Jude Angio-Seal Sales
This article was originally published in The Gray Sheet
Executive Summary
A 34% increase in Angio-Seal royalties from distributor St. Jude during the quarter ended Dec. 31 helped Kensey Nash's stock price advance 8.2% in January. The issue climbed $1.47 to close at $19.47 for the month
You may also be interested in...
Silicone Breast Implant Return To U.S. Market Heralded By Modular PMA
Inamed likely will be first to the U.S. market with a silicone gel-filled breast implant in the wake of FDA's 1992 call for PMAs for the pre-amendments devices
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.